SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,671,660 | -56.2% | 227,000 | 0.0% | 0.03% | -57.1% |
| Q2 2023 | $10,673,540 | +207.1% | 227,000 | +152.2% | 0.08% | +220.8% |
| Q1 2023 | $3,475,908 | -57.6% | 90,000 | -51.4% | 0.02% | -57.1% |
| Q3 2021 | $8,200,000 | +4.2% | 185,058 | +33.6% | 0.06% | +3.7% |
| Q2 2021 | $7,872,000 | -34.5% | 138,568 | -4.2% | 0.05% | -46.0% |
| Q1 2021 | $12,020,000 | -3.9% | 144,647 | 0.0% | 0.10% | +1.0% |
| Q4 2020 | $12,514,000 | +37.1% | 144,647 | -3.1% | 0.10% | +15.1% |
| Q3 2020 | $9,125,000 | +78.7% | 149,300 | +3632.5% | 0.09% | +59.3% |
| Q2 2020 | $5,106,000 | -51.5% | 4,000 | -97.3% | 0.05% | -53.8% |
| Q1 2020 | $10,536,000 | -2.2% | 149,300 | 0.0% | 0.12% | +0.9% |
| Q4 2019 | $10,778,000 | -44.8% | 149,300 | +7.2% | 0.12% | -55.2% |
| Q3 2019 | $19,542,000 | -9.4% | 139,300 | +17.8% | 0.26% | -3.7% |
| Q2 2019 | $21,564,000 | -24.0% | 118,300 | -33.7% | 0.27% | -25.9% |
| Q1 2019 | $28,360,000 | +84.7% | 178,300 | +11.2% | 0.36% | +53.8% |
| Q4 2018 | $15,354,000 | -21.1% | 160,300 | +16.3% | 0.24% | -8.9% |
| Q3 2018 | $19,464,000 | +120.5% | 137,800 | +144.3% | 0.26% | +85.0% |
| Q2 2018 | $8,829,000 | +44.2% | 56,400 | +48.4% | 0.14% | +34.6% |
| Q1 2018 | $6,121,000 | -2.2% | 38,000 | 0.0% | 0.10% | -3.7% |
| Q4 2017 | $6,259,000 | +86.1% | 38,000 | -29.6% | 0.11% | +83.1% |
| Q3 2017 | $3,364,000 | -33.0% | 54,000 | -14.3% | 0.06% | -37.2% |
| Q2 2017 | $5,018,000 | -3.3% | 63,000 | -13.7% | 0.09% | -6.0% |
| Q1 2017 | $5,188,000 | +217.5% | 73,000 | +128.1% | 0.10% | +170.3% |
| Q4 2016 | $1,634,000 | -9.0% | 32,000 | -17.9% | 0.04% | -14.0% |
| Q3 2016 | $1,796,000 | -19.5% | 39,000 | -47.3% | 0.04% | -25.9% |
| Q2 2016 | $2,230,000 | +1.4% | 74,000 | +7.2% | 0.06% | +5.5% |
| Q1 2016 | $2,200,000 | -50.5% | 69,000 | -9.4% | 0.06% | -53.8% |
| Q4 2015 | $4,442,000 | +58.5% | 76,200 | +15.1% | 0.12% | +72.5% |
| Q3 2015 | $2,802,000 | -46.7% | 66,200 | -8.1% | 0.07% | -36.7% |
| Q2 2015 | $5,256,000 | +32.4% | 72,000 | -8.9% | 0.11% | +36.2% |
| Q1 2015 | $3,969,000 | +66.8% | 79,000 | +21.5% | 0.08% | +60.0% |
| Q4 2014 | $2,379,000 | – | 65,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
| Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
| Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
| DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
| Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
| Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
| Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
| Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
| Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
| SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |